Tyra Biosciences Inc TYRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference
-
Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer
-
TYRA Investors Have Opportunity to Join Tyra Biosciences, Inc. Securities Fraud Investigation with the Schall Law Firm
-
Tyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights
-
Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH)
-
Tyra Biosciences Gets Rare Pediatric Disease Designation For Achondroplasia Therapy
Trading Information
- Previous Close Price
- $23.40
- Day Range
- $22.92–23.90
- 52-Week Range
- $10.38–25.14
- Bid/Ask
- $23.30 / $23.38
- Market Cap
- $1.23 Bil
- Volume/Avg
- 91,777 / 169,640
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company’s in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 38
- Website
- https://www.tyra.bio
Comparables
Valuation
|
Metric
|
TYRA
|
ORIC
|
BMEA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.27 | 2.38 | 3.45 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
TYRA
ORIC
BMEA
Financial Strength
|
Metric
|
TYRA
|
ORIC
|
BMEA
|
|---|---|---|---|
Quick Ratio | 36.00 | 14.66 | 0.00 |
Current Ratio | 36.46 | 15.08 | 4.62 |
Interest Coverage | — | — | — |
Quick Ratio
TYRA
ORIC
BMEA
Profitability
|
Metric
|
TYRA
|
ORIC
|
BMEA
|
|---|---|---|---|
Return on Assets (Normalized) | −21.10% | −31.05% | −62.52% |
Return on Equity (Normalized) | −22.29% | −33.92% | −73.48% |
Return on Invested Capital (Normalized) | −26.80% | −33.58% | −74.59% |
Return on Assets
TYRA
ORIC
BMEA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Vkfkwxvrly | Skkyg | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Yqbbjqt | Zxhzyvs | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gjbgrhzt | Jwdbz | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Pzylcnzh | Tdrqsh | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Srydqjmp | Plhd | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Hwtmyjqv | Nrwc | $28.1 Bil | |||
| Moderna Inc
MRNA
| Lmjbkks | Gzqg | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Yflvxvww | Xpwf | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Jtmmkwn | Ggmzfp | $13.4 Bil | |||
| Incyte Corp
INCY
| Rzzymrxr | Jnfbvf | $12.7 Bil |
United States